Aptorum Group Limited (NASDAQ:APM) Sees Significant Decrease in Short Interest

Aptorum Group Limited (NASDAQ:APM) saw a large decline in short interest in the month of January. As of January 15th, there was short interest totaling 1,025 shares, a decline of 61.8% from the December 31st total of 2,681 shares. Based on an average trading volume of 50,669 shares, the days-to-cover ratio is presently 0.0 days. Approximately 0.0% of the company’s shares are sold short. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 50,669 shares, the days-to-cover ratio is presently 0.0 days.

Aptorum Group Price Performance

APM opened at $0.85 on Thursday. Aptorum Group has a 12 month low of $0.69 and a 12 month high of $4.47. The business has a fifty day moving average price of $1.16 and a 200 day moving average price of $1.52.

Analyst Ratings Changes

APM has been the subject of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Aptorum Group in a research report on Monday, December 22nd. Wall Street Zen upgraded Aptorum Group from a “sell” rating to a “hold” rating in a research note on Saturday, October 11th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About Aptorum Group

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.